JP2023514323A5 - - Google Patents
Info
- Publication number
- JP2023514323A5 JP2023514323A5 JP2022549454A JP2022549454A JP2023514323A5 JP 2023514323 A5 JP2023514323 A5 JP 2023514323A5 JP 2022549454 A JP2022549454 A JP 2022549454A JP 2022549454 A JP2022549454 A JP 2022549454A JP 2023514323 A5 JP2023514323 A5 JP 2023514323A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978635P | 2020-02-19 | 2020-02-19 | |
| US62/978,635 | 2020-02-19 | ||
| PCT/US2021/018710 WO2021168197A1 (en) | 2020-02-19 | 2021-02-19 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026016996A Division JP2026074171A (ja) | 2020-02-19 | 2026-02-04 | インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023514323A JP2023514323A (ja) | 2023-04-05 |
| JPWO2021168197A5 JPWO2021168197A5 (https=) | 2024-02-27 |
| JP2023514323A5 true JP2023514323A5 (https=) | 2024-02-27 |
| JP7815127B2 JP7815127B2 (ja) | 2026-02-17 |
Family
ID=74870905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549454A Active JP7815127B2 (ja) | 2020-02-19 | 2021-02-19 | インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12528814B2 (https=) |
| EP (1) | EP4107158A1 (https=) |
| JP (1) | JP7815127B2 (https=) |
| KR (1) | KR20220155295A (https=) |
| CN (1) | CN115335381A (https=) |
| AU (1) | AU2021224923A1 (https=) |
| CA (1) | CA3165009A1 (https=) |
| TW (1) | TW202140489A (https=) |
| WO (1) | WO2021168197A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US11739101B2 (en) | 2020-05-06 | 2023-08-29 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
| FI4367118T3 (fi) * | 2021-08-18 | 2025-04-09 | Nurix Therapeutics Inc | Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö |
| EP4430052A1 (en) | 2021-11-10 | 2024-09-18 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
| AU2022405474A1 (en) * | 2021-12-08 | 2024-07-18 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications |
| WO2023186069A1 (zh) * | 2022-03-31 | 2023-10-05 | 石药集团中奇制药技术（石家庄）有限公司 | 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途 |
| CN119630802A (zh) | 2022-04-12 | 2025-03-14 | 建新公司 | Irak4调节剂用于基因疗法的用途 |
| CN117164583A (zh) * | 2022-05-20 | 2023-12-05 | 斯迈旭(苏州)生物科技有限公司 | 一种靶向irak4蛋白降解的化合物及其应用 |
| KR20260005340A (ko) * | 2023-05-30 | 2026-01-09 | 상하이 후이룬 파마슈티컬 컴퍼니 리미티드 | 트리시클릭 화합물, 이의 제조 방법 및 적용 |
| CN120202200A (zh) * | 2023-06-01 | 2025-06-24 | 标新生物医药科技(上海)有限公司 | 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用 |
| WO2025036451A1 (zh) * | 2023-08-15 | 2025-02-20 | 潘普洛纳生物科技（深圳）有限公司 | 靶向irak蛋白抑制或降解的化合物及其应用 |
| WO2025126115A1 (en) | 2023-12-13 | 2025-06-19 | Beigene Switzerland Gmbh | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use |
| WO2025149070A1 (zh) * | 2024-01-10 | 2025-07-17 | 甘李药业股份有限公司 | 一种新型靶向白细胞介素1受体关联激酶4(irak4)的蛋白降解嵌合体化合物的合成及其应用 |
| CN118406019B (zh) * | 2024-07-02 | 2024-09-20 | 苏州源起材料科技有限公司 | 一种噻唑化合物生物医药砌块的合成方法 |
| WO2026050190A1 (en) * | 2024-08-27 | 2026-03-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Smyd3 protacs for the treatment of hpv-negative squamous cell carcinoma |
| CN119119080A (zh) * | 2024-09-06 | 2024-12-13 | 上海信诺维生物医药有限公司 | 一种irak4的蛋白降解剂 |
| CN120757537B (zh) * | 2025-09-09 | 2026-01-06 | 广东省科学院动物研究所 | Protac降解剂及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7041298B2 (en) | 2000-09-08 | 2006-05-09 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7030112B2 (en) | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| CN104254533B (zh) * | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
| US9464326B2 (en) | 2012-03-22 | 2016-10-11 | University Of Maryland, Baltimore | Total and phosphorylated IL-1 receptor-associated kinase-1 and IL-1 receptor-associated kinase-4 as a biomarker for cancer progression and chemotherapy resistance |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TW201718571A (zh) * | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| ES2822956T3 (es) * | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| US10487329B2 (en) | 2015-10-29 | 2019-11-26 | Children's Hospital Medical Center | Methods and compositions for the treatment of head and neck cancer |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP3532164A4 (en) | 2016-10-28 | 2020-10-07 | Children's Hospital Medical Center | TREATMENT OF IRAQ ASSOCIATED DISEASES ACTIVATED |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| WO2018232288A1 (en) | 2017-06-16 | 2018-12-20 | Genentech, Inc. | Diagnostic and therapeutic methods for irak4-mediated disorders and conditions |
| US11065231B2 (en) * | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019103196A1 (ko) | 2017-11-24 | 2019-05-31 | 엘지전자 주식회사 | 무선 통신 시스템에서 빔을 리포팅하는 방법 및 장치 |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019160915A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| US20200038513A1 (en) | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| WO2020036830A1 (en) * | 2018-08-13 | 2020-02-20 | Gilead Sciences, Inc. | Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors |
| TWI727392B (zh) | 2018-08-13 | 2021-05-11 | 美商基利科學股份有限公司 | 噻二唑irak4抑制劑 |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4038066A1 (en) | 2019-10-01 | 2022-08-10 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2021180103A1 (en) | 2020-03-11 | 2021-09-16 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| MX2022016061A (es) | 2020-06-17 | 2023-02-02 | Kymera Therapeutics Inc | Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos. |
| WO2021255212A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Braf degraders |
| CA3217892A1 (en) | 2021-05-03 | 2022-11-10 | Joel Mcintosh | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| FI4367118T3 (fi) | 2021-08-18 | 2025-04-09 | Nurix Therapeutics Inc | Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö |
-
2021
- 2021-02-19 EP EP21711431.3A patent/EP4107158A1/en active Pending
- 2021-02-19 CN CN202180015953.3A patent/CN115335381A/zh active Pending
- 2021-02-19 WO PCT/US2021/018710 patent/WO2021168197A1/en not_active Ceased
- 2021-02-19 CA CA3165009A patent/CA3165009A1/en active Pending
- 2021-02-19 KR KR1020227031406A patent/KR20220155295A/ko active Pending
- 2021-02-19 TW TW110105770A patent/TW202140489A/zh unknown
- 2021-02-19 JP JP2022549454A patent/JP7815127B2/ja active Active
- 2021-02-19 US US17/904,592 patent/US12528814B2/en active Active
- 2021-02-19 AU AU2021224923A patent/AU2021224923A1/en active Pending